AngioDynamics ANGO has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid first-quarter fiscal 2026 performance, ...

AngioDynamics, Inc.’s ANGO investors have been experiencing some short-term losses from the stock of late. Shares of the Latham, NY-based medical technology company have plunged 13.8% in the past ...

AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected adjusted loss, but its GAAP loss was much bigger. AngioDynamics lost money in ...

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty. However, the company's business ...

AngioDynamics (NASDAQ: ANGO) stock soared 10.5% through 11:25 a.m. ET Thursday after beating on "earnings" (sort of) this morning. Heading into the report, analysts forecast AngioDynamics would lose ...

AngioDynamics posted Q3 adjusted EPS of $0.03, beating the $(0.13) loss expected. Sales rose 9.2% to $72M, surpassing the $70.3M consensus. Med Tech net sales grew 22.2% to $31.3M, with Auryon up 17.3 ...

AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2. Analysts expect the Latham, New York-based company to report a ...

AngioDynamics reported mixed fiscal 2025 Q1 results. The medical technology company has had some good news recently, though. AngioDynamics continues to expect modest growth for the full year.